Profound Medical Corp. $PROF

What the company doesAI summary of filing

Profound Medical is a commercial-stage medical device company that develops and markets MRI-guided, incision-free ablation systems for treating diseased tissue. The company's lead product, the TULSA-PRO system, received FDA clearance in August 2019 for thermal ablation of prostate tissue and is CE marked in the EU; it combines real-time MRI, robotically-driven ultrasound, and temperature feedback control. The company's second system, Sonalleve, is CE marked in the EU for treating uterine fibroids, bone metastases, osteoid osteoma, and desmoid tumors, with FDA approval for osteoid osteoma treatment. Profound generates revenues from capital equipment sales and recurring revenue from single-use devices and related services, primarily in the United States, EU, and Asia. [10-K 2026-03-05]

Segments: TULSA-PRO system (prostate ablation), Sonalleve system (uterine fibroids, bone metastases, osteoid osteoma, desmoid tumors)